ZIRABEV

(Zirabev)

Phase 2Small molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

ZIRABEV is one of 37 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Vizimpro

Pfizer

Preclinical

4 7

Gilotrif

Boehringer Ingelheim

Preclinical

12 8

Ofev

Boehringer Ingelheim

Preclinical

7 9

ZIRABEV

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 10

Immunotherapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT05601973

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Active, not recruiting·EETOP IBCSG Partners Foundation·Phase 2·NCT05601973·60 enrolled

Effectiveness1 trial

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Withdrawn· Pfizer logo

Pfizer··NCT04889495

Regulatory

FDA Approval Timeline[4]

Jun 27, 2019

ZIRABEV

BLA BLA761099

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Zirabev. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zirabev compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zirabev. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761099). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

ZIRABEV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Effectiveness1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News